MOTS-C (40mg)
MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) studied as a metabolic regulator via AMPK activation. Research-use literature describes subcutaneous administration of 5 mg, 2–3 times weekly, in 4–8 week cycles.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full MOTS-c encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
MOTS-c functions as a metabolic 'stress signal' that helps optimize energy utilization. The primary mechanism is **AMPK activation** via inhibition of the folate cycle, causing an accumulation of AICAR. AMPK activation shifts cells into an energy-efficient mode—enhancing glucose uptake, fatty acid oxidation, and mitochondrial respiration. It can also translocate to the nucleus under stress conditions and upregulate antioxidant genes.
Quick Start
- Reconstitution: Add 4.0 mL bacteriostatic water → 10 mg/mL concentration.
- Literature-reported range: 5 mg per injection, 2–3 times weekly (10–15 mg/week).
- Easy measurement: At 10 mg/mL, 5 mg = 50 units (0.50 mL) on a U-100 syringe.
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C, use within 28 days.
Literature-reported ranges (4.0 mL = 10 mg/mL)
Route: Subcutaneous | Frequency: 2–3 times weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 5 mg | 50 Units (0.50 mL) |
| Weeks 3–8 | 5 mg | 50 Units (0.50 mL) |
Research-use literature reports subcutaneous administration 2–3 times weekly (e.g., Monday/Wednesday/Friday) in 4–8 week cycles with a 4-week break. There is no validated human dosing.
Related compounds
Reconstitution Steps
- Draw 4.0 mL of bacteriostatic water.
- Inject slowly down the vial wall; avoid foaming.
- Swirl gently until fully dissolved — do not shake.
- Note the reconstitution date and refrigerate at 2–8 °C.
Protocol Overview
- Literature-reported scope: Metabolic homeostasis, insulin sensitivity and physical performance (mostly preclinical data).
- Literature-described schedule: 5 mg subcutaneously, 2–3 times weekly, for 4–8 weeks.
- Doses per vial: 8 × 5 mg.
Dosing Protocol
- Weeks 1–2: 5 mg × 2/week (10 mg/week).
- Weeks 3–8: 5 mg × 3/week (15 mg/week).
- Literature-described break: 4 weeks after each cycle.
- There is no validated human dosing — research context only.
- Break between cycles: After a 4–8 week cycle, the literature describes a 4-week break.
Washout & Cycle Restart
When can I restart?
After a 4–8 week cycle, the literature describes a 4-week break.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C in dry, dark conditions.
- Reconstituted: 2–8 °C; use within 28 days.
- Avoid freeze-thaw cycles.
Important Notes
- Log dose, site, and observations at each injection.
- Discontinue and consult a physician if any concerning symptoms appear.
Potential Benefits & Side Effects
Potential Benefits:
- Improved insulin sensitivity and glucose metabolism in mouse models
- Obesity prevention – reduced visceral fat via increased energy expenditure
- Enhanced physical performance – aged mice ran 2× longer
- Organ protection: reduction in liver fat, improved cardiac function
- Bone & immune: promotes osteoblasts, regulates immune senescence
Potential Side Effects:
- No reported adverse effects in preclinical studies
- Human tolerability is unknown – no comprehensive clinical trials exist
- Modified analog (CB4211) showed good tolerability in Phase 1
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
AMPK regulation — effect on glucose metabolism
MOTS-c activates AMPK and modifies glucose metabolism. Combined with antidiabetic drugs, may theoretically cause hypoglycemia. Very few human studies.
📄 Cell Metab 2015References
- Cell Metabolism (2015) — MOTS-c promotes metabolic homeostasis – reduction of obesity and insulin resistance
View Source - Journal of Translational Medicine (2023) — MOTS-c: effects on stress, metabolism, and aging
View Source - Nature Communications (2021) — MOTS-c regulates age-dependent physical decline and muscle homeostasis
View Source - USADA (2023) — What is the MOTS-c peptide – an educational article
View Source
Recommended Supplements
NMN (Nicotinamide Mononucleotide)
CoQ10 (Ubiquinol)
Vitamin E (Mixed Tocopherols)
External Sources & Regulatory Status
Regulatory Approvals
Research-only — Mitochondrial peptide
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →